Achieving ≤ 10% IS BCR-ABL* is associated with long-term survival in CML

Achievement of ≤ 10% International Scale (IS) BCR-ABL at 3 months is associated with overall survival (OS) at 8 years1

  • Patients with BCR-ABL transcript levels > 10% IS at 3 months had lower OS than those with ≤ 10% IS1

8-year OS according to 10% IS BCR-ABL at 3 months1

IS BCR-ABL at 3 Months 8 Year OS

*IS BCR-ABL refers to the ratio of BCR-ABL to ABL transcripts (or other internationally recognized control transcript) expressed and reported as a percentage of the International Scale.4

Monitor the Milestones Matters

Real-time quantitative polymerase chain reaction (RQ-PCR) is a highly sensitive means of measuring BCR-ABL levels2

  • BCR-ABL levels can be evaluated using peripheral blood with IS RQ-PCR3
  • IS RQ-PCR testing can help identify patients who have not reached the 3-month milestone and may require more frequent monitoring4
  1. Marin D, et al. J Clin Oncol. 2012;30(3):232-238.
  2. Zhen C, et al. J Mol Diagn. 2013;15(5):556-564.
  3. Akard LP, et al. Clin Lymphoma Myeloma Leuk. 2011;11(5):385-395.
  4. Baccarani M, et al. Blood. 2013;122(6):872-884.